Lagatar24 Desk
New Delhi, March 9: The Biological E, a Hyderabad-based pharmaceutical business on Wednesday has asked for an Emergency Use Authorisation (EUA) for its COVID-19 vaccine Corbevax for children aged 5 to 12.
The business submitted data to the Subject Expert Committee for beneficiaries aged 5 to 12. The Subject Expert Committee recently recommended Emergency Use Authorization (EUA) for Biological E’s COVID-19 vaccine Corbevax for the age range of 12 to 18 years under specified conditions.
Corbevax is likely to receive a final EUA from the Drugs Controller General of India (DCGI) soon. The SEC only recommended EUA after reviewing the group’s safety and immunogenicity data.
The vaccine is projected to cost 145 dollars before taxes. It will be given two times at predetermined intervals.
The central government has already procured and delivered approximately 5 crore Biological E vaccinations Corbevax to several states, according to the sources.
Biological E, a vaccine developer, applied for phase 2 and phase 3 clinical trials in September of last year.
Meanwhile on Wednesday, India’s Ministry of Health and Family Welfare recorded 4,575 new COVID-19 cases in the previous 24 hours.
